Baidu
map

Brit J Cancer:接受治疗的前列腺癌患者心血管事件风险

2019-05-08 xing.T 网络

由此可见,生活方式、人体测量学指标或心血管危险因素并未解释接受姑息治疗的PCa患者的IS和HF风险。结果强调了在该患者组中平衡疾病管理和监测心血管健康的必要性。

生活方式、人体测量学指标和血管危险因素对前列腺癌(PCa)男性患者血管疾病的影响仍不清楚。

近日,肿瘤领域权威杂志British Journal of Cancer上发表了一篇研究文章,研究人员使用基于人群队列中的25436名年龄在50-64岁的丹麦无癌症男性进行分析,并获得了自我报告的癌症前期生活方式、客观测量的人体测量学指标和心血管危险因素的信息,以及将其与国家健康登记中心进行连接,以获取主要心血管结局的相关信息。研究人员评估了1546例诊断为PCa并接受一线主动监测、观察等待、预期治愈或姑息治疗的患者与无PCa的男性患者相比在18年随访期间急性心肌梗死(MI)、缺血性卒中(IS)和心力衰竭(HF)的风险比(HR)。 

与无PCa的男性相比,接受一线姑息治疗的男性IS和HF的发生率分别为2.09(95%CI为1.49-2.93)和2.05(95%CI为1.43-2.94)。从治疗开始,风险增加。研究人员在任何其他治疗组中找不到与男性相同的关系。在调整生活方式、人体测量学指标和心血管危险因素后,观察到治疗的PCa患者和无癌症对照男性之间没有差异。 

由此可见,生活方式、人体测量学指标或心血管危险因素并未解释接受姑息治疗的PCa患者的IS和HF风险。结果强调了在该患者组中平衡疾病管理和监测心血管健康的必要性。 

原始出处:

Ida Rask Moustsen,et al.Risk of cardiovascular events in men treated for prostate cancer compared with prostate cancer-free men.British Journal of Cancer. 2019.https://www.nature.com/articles/s41416-019-0468-8

本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1643609, encodeId=bd1a164360927, content=<a href='/topic/show?id=6236895092b' target=_blank style='color:#2F92EE;'>#血管事件#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89509, encryptionId=6236895092b, topicName=血管事件)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f99523187183, createdName=hukaixun, createdTime=Thu Nov 21 05:39:00 CST 2019, time=2019-11-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1287664, encodeId=ed46128e66405, content=<a href='/topic/show?id=3c3d51e4459' target=_blank style='color:#2F92EE;'>#心血管事件风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=51744, encryptionId=3c3d51e4459, topicName=心血管事件风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3138208, createdName=zhanfl, createdTime=Fri May 10 10:39:00 CST 2019, time=2019-05-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=365946, encodeId=d7c636594615, content=好, beContent=null, objectType=article, channel=null, level=null, likeNumber=119, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18741984753, createdName=smartxiuxiu, createdTime=Thu May 09 07:39:22 CST 2019, time=2019-05-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1040448, encodeId=ad1c1040448b1, content=前列腺癌相关研究,学习了,谢谢梅斯, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Wed May 08 22:39:00 CST 2019, time=2019-05-08, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1643609, encodeId=bd1a164360927, content=<a href='/topic/show?id=6236895092b' target=_blank style='color:#2F92EE;'>#血管事件#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89509, encryptionId=6236895092b, topicName=血管事件)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f99523187183, createdName=hukaixun, createdTime=Thu Nov 21 05:39:00 CST 2019, time=2019-11-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1287664, encodeId=ed46128e66405, content=<a href='/topic/show?id=3c3d51e4459' target=_blank style='color:#2F92EE;'>#心血管事件风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=51744, encryptionId=3c3d51e4459, topicName=心血管事件风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3138208, createdName=zhanfl, createdTime=Fri May 10 10:39:00 CST 2019, time=2019-05-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=365946, encodeId=d7c636594615, content=好, beContent=null, objectType=article, channel=null, level=null, likeNumber=119, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18741984753, createdName=smartxiuxiu, createdTime=Thu May 09 07:39:22 CST 2019, time=2019-05-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1040448, encodeId=ad1c1040448b1, content=前列腺癌相关研究,学习了,谢谢梅斯, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Wed May 08 22:39:00 CST 2019, time=2019-05-08, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1643609, encodeId=bd1a164360927, content=<a href='/topic/show?id=6236895092b' target=_blank style='color:#2F92EE;'>#血管事件#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89509, encryptionId=6236895092b, topicName=血管事件)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f99523187183, createdName=hukaixun, createdTime=Thu Nov 21 05:39:00 CST 2019, time=2019-11-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1287664, encodeId=ed46128e66405, content=<a href='/topic/show?id=3c3d51e4459' target=_blank style='color:#2F92EE;'>#心血管事件风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=51744, encryptionId=3c3d51e4459, topicName=心血管事件风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3138208, createdName=zhanfl, createdTime=Fri May 10 10:39:00 CST 2019, time=2019-05-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=365946, encodeId=d7c636594615, content=好, beContent=null, objectType=article, channel=null, level=null, likeNumber=119, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18741984753, createdName=smartxiuxiu, createdTime=Thu May 09 07:39:22 CST 2019, time=2019-05-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1040448, encodeId=ad1c1040448b1, content=前列腺癌相关研究,学习了,谢谢梅斯, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Wed May 08 22:39:00 CST 2019, time=2019-05-08, status=1, ipAttribution=)]
    2019-05-09 smartxiuxiu

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1643609, encodeId=bd1a164360927, content=<a href='/topic/show?id=6236895092b' target=_blank style='color:#2F92EE;'>#血管事件#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89509, encryptionId=6236895092b, topicName=血管事件)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f99523187183, createdName=hukaixun, createdTime=Thu Nov 21 05:39:00 CST 2019, time=2019-11-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1287664, encodeId=ed46128e66405, content=<a href='/topic/show?id=3c3d51e4459' target=_blank style='color:#2F92EE;'>#心血管事件风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=51744, encryptionId=3c3d51e4459, topicName=心血管事件风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3138208, createdName=zhanfl, createdTime=Fri May 10 10:39:00 CST 2019, time=2019-05-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=365946, encodeId=d7c636594615, content=好, beContent=null, objectType=article, channel=null, level=null, likeNumber=119, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18741984753, createdName=smartxiuxiu, createdTime=Thu May 09 07:39:22 CST 2019, time=2019-05-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1040448, encodeId=ad1c1040448b1, content=前列腺癌相关研究,学习了,谢谢梅斯, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Wed May 08 22:39:00 CST 2019, time=2019-05-08, status=1, ipAttribution=)]
    2019-05-08 misszhang

    前列腺癌相关研究,学习了,谢谢梅斯

    0

相关资讯

Cancer:糖尿病不良控制能够增加去势抵抗性前列腺癌和转移的风险

尽管糖尿病与前列腺癌(PC)风险呈现负相关关系,但是血糖控制对PC进展的的影响仍旧未知。最近,有研究人员在经历根治性前列腺切除(RP)男性糖尿病患者中,探究了血红蛋白A1c(HbA1c)和长期PC结果之间的相关性。研究共有1409名男性,其中699名患者(50%)HbA1c值<6.5%,631名(45%)患者的HbA1c值为6.5%到7.9%之间,79名(6%)患者的HbA1c值不小于8%。

Oncogenesis:ZFHX3对ERβ抑制细胞增殖是必不可少的

雌激素受体2(ESR2,也称之为ERβ)和锌指同源框3(ZFHX3,也称之为ATBF1)在小鼠中能够调控前列腺发育和抑制前列腺肿瘤的形成。ZFHX3对ESR1的功能是不可或缺的,ESR1与ESR2属于同一家族蛋白,但是在前列腺上皮中几乎不表达。ZFHX3怎样抑制前列腺致瘤过程仍旧不清楚。最近,有研究人员调查了是否ZFHX3和ERβ在抑制前列腺致瘤过程中存在互作。在C4-2B和LNCaP雄激素受体(

降低肿瘤转移和死亡风险近60%,前列腺癌新药获优先审评资格

拜耳(Bayer)公司和Orion公司宣布,美国FDA接受了该公司为雄激素受体(AR)拮抗剂darolutamide递交的新药申请(NDA),用于治疗非转移性去势抵抗性前列腺癌(nmCRPC)患者。

2019年AUA:临床前数据突显EPI-7386治疗前列腺癌的潜力

ESSA是一家专注于开发前列腺癌治疗新疗法的制药公司,近日宣布,将在2019年美国泌尿学会(AUA)年会上公布新一代N末端域雄激素受体抑制剂EPI-7386在去势抵抗前列腺癌模型中的有效性数据。

Prostate Cancer P D:改善前列腺活检患者风险评估和选择的预测模型研究

前列腺癌风险预测模型和多参数核磁共振成像(mpMRI)能够用于个性化的活检前风险评估。然而,双参数MRI(bpMRI)已经成为一种更加简单、更加迅速的MRI方法来减少花费并促进其在临床中的应用。bpMRI和风险模型怎样结合起来还是未知。最近,有研究人员基于bpMRI和临床参数为无活检历史的明显前列腺癌(sPCa)患者开发了一个预测模型。研究包括了876名无活检且具有临床疑似前列腺癌的男性(PSA&

Bayer/Orion的非甾体雄激素受体拮抗剂darolutamide治疗前列腺癌获得FDA优先审查

美国食品和药物管理局(FDA)已接受新的药物申请审查,并给予darolutamide优先审查。

Baidu
map
Baidu
map
Baidu
map